论文部分内容阅读
制药工业在世界上无论哪一个国家都经受着考验。由于存在药品价格限制、有效专利期短、一般药品增多、医师选定商品的限制等问题,所以给制药工业带来很多困难。伦敦的健康经济办公室会同西德医药研究协会进行协作,总结了制药工业面临的各种问题写成书面报告。现在从其中选择研究开发部分的主要点加以介绍。谈到研究开发时,首先研究开发药物所投予的的费用是非常必要的,从美国、英国、西德、意大利、法国、瑞士、日本七国来看,1964年以后到1982年止,各国制药工业投资逐渐增多。美国约增
The pharmaceutical industry in any country in the world has stood the test. Due to the restrictions on the price of medicines, the short effective patent period, the increase of general medicines and the limitation of physicians’ selection of commodities, the pharmaceutical industry poses many difficulties. The London Office of Health Economics, in collaboration with the West German Institute for Medical Research, summarizes various issues facing the pharmaceutical industry in written form. Now I will introduce the main points in the research and development section. When it comes to research and development, it is necessary to study the costs of drug development first. From the perspective of the United States, Britain, West Germany, Italy, France, Switzerland and Japan, from 1964 to 1982, all countries Pharmaceutical industry investment gradually increased. U.S. increased